Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148685331> ?p ?o ?g. }
- W2148685331 endingPage "203" @default.
- W2148685331 startingPage "7196" @default.
- W2148685331 abstract "The type I receptor tyrosine kinases constitute a family of transmembrane proteins involved in various aspects of cell growth and survival and have been implicated in the initiation and progression of several types of human malignancies. The best characterized of these proteins are the epidermal growth factor receptor (EGFR) and ErbB-2 (HER-2/neu). We have developed potent quinazoline and pyrido-[3,4-d]-pyrimidine small molecules that are dual inhibitors of ErbB-2 and EGFR. The compounds demonstrate potent in vitro inhibition of the ErbB-2 and EGFR kinase domains with IC(50)s <80 nM. Growth of ErbB-2- and EGFR-expressing tumor cell lines is inhibited at concentrations <0.5 microM. Selectivity for tumor cell growth inhibition versus normal human fibroblast growth inhibition ranges from 10- to >75-fold. Tumor growth in mouse s.c. xenograft models of the BT474 and HN5 cell lines is inhibited in a dose-responsive manner using oral doses of 10 and 30 mg/kg twice per day. In addition, the tested compounds caused a reduction of ErbB-2 and EGFR autophosphorylation in tumor fragments from these xenograft models. These data indicate that these compounds have potential use as therapy in the broad population of cancer patients overexpressing ErbB-2 and/or EGFR." @default.
- W2148685331 created "2016-06-24" @default.
- W2148685331 creator A5007659606 @default.
- W2148685331 creator A5008059325 @default.
- W2148685331 creator A5010748193 @default.
- W2148685331 creator A5011308777 @default.
- W2148685331 creator A5014568050 @default.
- W2148685331 creator A5027482286 @default.
- W2148685331 creator A5030786882 @default.
- W2148685331 creator A5045049923 @default.
- W2148685331 creator A5045818811 @default.
- W2148685331 creator A5047978666 @default.
- W2148685331 creator A5052713970 @default.
- W2148685331 creator A5054114557 @default.
- W2148685331 creator A5056446970 @default.
- W2148685331 creator A5057816995 @default.
- W2148685331 creator A5067316222 @default.
- W2148685331 creator A5070025152 @default.
- W2148685331 creator A5073497484 @default.
- W2148685331 creator A5074075692 @default.
- W2148685331 creator A5074373932 @default.
- W2148685331 creator A5079899024 @default.
- W2148685331 creator A5081108237 @default.
- W2148685331 creator A5082855062 @default.
- W2148685331 creator A5082858422 @default.
- W2148685331 creator A5088485595 @default.
- W2148685331 creator A5088772122 @default.
- W2148685331 date "2001-10-01" @default.
- W2148685331 modified "2023-10-01" @default.
- W2148685331 title "The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer." @default.
- W2148685331 cites W141806765 @default.
- W2148685331 cites W1505534997 @default.
- W2148685331 cites W1550092936 @default.
- W2148685331 cites W1592990112 @default.
- W2148685331 cites W167124021 @default.
- W2148685331 cites W1779286308 @default.
- W2148685331 cites W180715779 @default.
- W2148685331 cites W1890809256 @default.
- W2148685331 cites W192295639 @default.
- W2148685331 cites W1939364580 @default.
- W2148685331 cites W1983790923 @default.
- W2148685331 cites W1985827132 @default.
- W2148685331 cites W1995680891 @default.
- W2148685331 cites W2016323110 @default.
- W2148685331 cites W2020724252 @default.
- W2148685331 cites W2026907934 @default.
- W2148685331 cites W2030415021 @default.
- W2148685331 cites W2040123299 @default.
- W2148685331 cites W2044416896 @default.
- W2148685331 cites W2059031630 @default.
- W2148685331 cites W2060447952 @default.
- W2148685331 cites W2062589393 @default.
- W2148685331 cites W2066660777 @default.
- W2148685331 cites W2077374035 @default.
- W2148685331 cites W2078611937 @default.
- W2148685331 cites W2093222764 @default.
- W2148685331 cites W2094703210 @default.
- W2148685331 cites W2095156669 @default.
- W2148685331 cites W2105847083 @default.
- W2148685331 cites W2123206362 @default.
- W2148685331 cites W2134611286 @default.
- W2148685331 cites W2141393790 @default.
- W2148685331 cites W2159848663 @default.
- W2148685331 cites W2163402367 @default.
- W2148685331 cites W2275508015 @default.
- W2148685331 cites W2286614396 @default.
- W2148685331 cites W2416310597 @default.
- W2148685331 cites W2462952870 @default.
- W2148685331 cites W2471344222 @default.
- W2148685331 cites W2764822961 @default.
- W2148685331 cites W629275675 @default.
- W2148685331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11585755" @default.
- W2148685331 hasPublicationYear "2001" @default.
- W2148685331 type Work @default.
- W2148685331 sameAs 2148685331 @default.
- W2148685331 citedByCount "75" @default.
- W2148685331 countsByYear W21486853312012 @default.
- W2148685331 countsByYear W21486853312013 @default.
- W2148685331 countsByYear W21486853312014 @default.
- W2148685331 countsByYear W21486853312015 @default.
- W2148685331 countsByYear W21486853312016 @default.
- W2148685331 countsByYear W21486853312017 @default.
- W2148685331 countsByYear W21486853312018 @default.
- W2148685331 countsByYear W21486853312019 @default.
- W2148685331 countsByYear W21486853312020 @default.
- W2148685331 countsByYear W21486853312021 @default.
- W2148685331 countsByYear W21486853312022 @default.
- W2148685331 countsByYear W21486853312023 @default.
- W2148685331 crossrefType "journal-article" @default.
- W2148685331 hasAuthorship W2148685331A5007659606 @default.
- W2148685331 hasAuthorship W2148685331A5008059325 @default.
- W2148685331 hasAuthorship W2148685331A5010748193 @default.
- W2148685331 hasAuthorship W2148685331A5011308777 @default.
- W2148685331 hasAuthorship W2148685331A5014568050 @default.
- W2148685331 hasAuthorship W2148685331A5027482286 @default.
- W2148685331 hasAuthorship W2148685331A5030786882 @default.
- W2148685331 hasAuthorship W2148685331A5045049923 @default.
- W2148685331 hasAuthorship W2148685331A5045818811 @default.